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Abstract 
Objectives: The aim of this study was to assess the validity, reliability, and factor structure 
of the Impact of Female Chronic Pelvic Pain Questionnaire (IF-CPPQ).  
Methods: This was a cross-sectional questionnaire study that was administered online. To 
be eligible to participate, women had to have experienced chronic pelvic pain (CPP) for a 
minimum of three months and be at least 18 years of age. A total of 969 women (mean age 
35.4 years, SD = 12.0) took part. The main outcome measure was the IF-CPPQ. Additional 
validated measures that assessed related constructs were also administered. Principal axis 
factor analysis (PAF) was used to assess the factor structure of the IF-CPPQ. Internal 
consistency was assessed using Cronbach’s alpha. Convergent and discriminant validity was 
assessed using Pearson correlations between factor scores on the IF-CPPQ and measures of 
related constructs. The consistency and model fit of the resulting factor structure was 
assessed using confirmatory factor analysis.  
Results: The final 26-item questionnaire comprised five factors (Psychological Impact, Sexual 
Impact, Relationship Impact, Occupational Impact, and Emotional Impact). Findings 
suggested good convergent and discriminant validity and internal consistency.  
Discussion: The findings indicate that the IF-CPPQ is a reliable and valid measure of the 
impact of CPP on women. While the IF-CPPQ has the potential for multiple uses within 
research and clinical practice, further research is needed to determine the questionnaire’s 
ability to detect clinically meaningful changes with treatment. 
 
Keywords: Chronic pelvic pain; Questionnaire; Quality of Life; Psychometric; Factor Analysis; 
Validation; Reliability 
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Introduction 
Chronic pelvic pain (CPP) is one of the most common pain problems experienced by 
women and is associated with several gynaecological conditions (1-3). It can be defined as 
intermittent or constant pain in the lower abdomen or pelvis of at least 6 months in 
duration and is associated with negative cognitive, behavioural, sexual and emotional 
consequences (4, 5). Despite a high prevalence rate, (6) CPP is still poorly understood and 
difficult to diagnose (7). Several studies have assessed the impact of CPP. Women with CPP 
have significantly lower levels of sexual satisfaction and sexual activity (8) and higher rates 
of anxiety and depression compared to healthy controls (9). 
Most studies assess the impact of CPP using study-specific (10, 11) or generic quality 
of life measures (QoL) (8, 9, 12). Generic measures have shown poor face validity when 
administered to women with CPP (13). Some questionnaires focus on specific CPP 
conditions e.g., endometriosis, (14, 15) interstitial cystitis, (16) pelvic pain and urinary 
symptoms, (17), irritable bowel syndrome (IBS) (18, 19), and vulvodynia (20). Although 
useful for evaluating the impact of disease-specific symptoms on QoL, these questionnaires 
focus on pain characteristics such as intensity and duration rather than the impact of the 
pain (16, 17). Most also do not consider the broad range of areas that may be affected by 
CPP, such as work, relationships, and emotional wellbeing (17) and few measures evaluate 
the impact of CPP on intimate relationships (21-23). Questionnaires developed to assess CPP 
regardless of diagnosis include the CPP Questionnaires (24) and the CPP Questionnaire 
(CPPQ)-Mohedo test (25). However, these measures were developed primarily as screening 
tools and neither assesses the psychological, relationship, or sexual impact of CPP. 
The Endometriosis health Profile (EHP)-30 (26) is one of the very few patient-
generated questionnaires in this area. The final questionnaire includes several important 
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domains such as the impact on work, perceptions of the medical profession, infertility, 
social support, and control and powerlessness. The EHP-30 has been found to have good 
internal consistency, construct validity, and test-retest reliability (26, 27). However, this 
questionnaire was designed specifically for women with endometriosis and therefore may 
not be suitable for women with CPP who do not have endometriosis.  
Another comprehensive measure is the Vulvar Pain Assessment Questionnaire 
(VPAQ) (20). The VPAQ assesses cognitive/emotional functioning, physical functioning, 
coping skills, partner factors, and pain characteristics experienced by women with chronic 
vulvar pain. While a number of domains are assessed, the VPAQ is predominantly aimed at 
women with chronic vulvar pain rather than CPP more broadly.  
Currently there is no existing measure that assesses the impact of CPP on women’s 
lives that is suitable for women with different diagnoses. Disease-specific questionnaires can 
only be used by women with a clear diagnosis, which can take many years to obtain. CPP has 
been considered a syndrome in its own right (2, 11, 24). As health QoL assessments made by 
patients can differ from those of healthcare professionals, (13, 28) development of 
measures should be informed by women who experience CPP. 
To address this need, the Impact of Female Chronic Pelvic Pain Questionnaire (IF-
CPPQ) was developed to assess the impact of CPP on women’s lives. The items were 
generated based on qualitative interviews with women experiencing CPP (29, 30) and have 
been piloted in think-aloud interviews (31).  
The aim of the current study was to assess the validity, reliability, and factor 
structure of the newly developed IF-CPPQ. Quality criteria for instrument properties are 
important. Such criteria can help determine the methodological quality of studies and are 
useful for the evaluation of different measures. Terwee, Bot, and de Boer et al. (32) defined 
 6 
a set of quality criteria for measurement properties for the development of health status 
questionnaires. The quality criteria include the following measurement properties: content 
validity; internal consistency; criterion validity; construct validity; reproducibility; 
responsiveness; floor and ceiling effects; and interpretability (32). These quality criteria 
were used in the design of this study to help ensure quality in the development of the new 
CPP measure.  
Materials and Methods 
Participants  
Inclusion criteria included experience of CPP (i.e. intermittent or constant pain in 
the lower abdomen or pelvis) for a minimum of six months and age at least 18 years (33). 
National UK and international charities who support individuals with CPP conditions were 
contacted and asked to distribute information about the study and advertisements were 
also placed on social media and in newspapers.  
There is a lack of agreement in the literature regarding the appropriate sample size 
for exploratory factor analysis (34). The appropriate sample size also depends on the 
number of items included, with a participant to item ratio of 10:1 recommended in order to 
reduce sampling error (35). According to Tabachnick and Fidell (36), at least 300 cases are 
sufficient for factor analysis. 
Measures 
 Participants provided demographic data (including age, ethnicity, religious affiliation, 
occupational status, highest level of education, relationship and marital status, and pain-
related diagnoses) and information about their average pain levels over a typical month 
(from 1 “no pain” to 10 “worst imaginable pain”).  
 IF-CPPQ 
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 In a previous qualitative study, one-to-one interviews were conducted with 25 
women experiencing CPP to explore the impact of the pain on their quality of life (29). The 
mean age of this sample was 36.6 (22-63) and participants had experienced pain for an 
average of 8.5 years. The main diagnoses included Endometriosis, Neuropathic pain/ 
Pudental neuralgia, Vulvodynia, and IBS. The data from these interviews were thematically 
analysed (37), which resulted in themes that covered the impact of CPP on multiple 
domains, including everyday functioning, mood, relationship satisfaction, sexual functioning, 
and occupational functioning. The development of the initial items for the IF-CPPQ was 
informed by the qualitative data obtained from these interviews. Specifically, the main 
themes that resulted from the qualitative data were selected as the main constructs to be 
measured by the new questionnaire. The initial questionnaire items were then generated 
based on these constructs and followed the principles outlined in Sudman and Bradburn 
(37). This led to the development of 72 items. Items were then removed and adjusted after 
gaining further feedback from women with CPP in a think-aloud study (27). The resulting 
questionnaire contained 52 items. A sample item is “I felt that I have not been “heard” or 
listened to by people close to me when I have talked about my pain.” Items are rated on a 
five-point scale (“Strongly agree,” “Agree,” “Neither agree nor disagree,” “Disagree,” and 
“Strongly disagree”). 
The Pain Disability Index (PDI) (38)  
This is a validated seven-item questionnaire (39) that assesses the degree to which 
pain interferes with various daily activities. The PDI was selected because some of the items 
on the IF-CPPQ assess the impact of CPP on everyday functioning, which relates to the 
constructs measured by the PDI. Responses are made on a scale of 0 to 10, with 0 indicating 
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“no disability” and 10 “total disability.” Scores on the PDI were expected to have positive 
correlations with the IF-CPPQ.  
The World Health Organization Quality of Life (WHOQOL)-BREF (40)  
This 26-item questionnaire assesses four domains of QOL: physical health, 
psychological, social relationships, and the environment and has good validity and reliability 
(40). The WHOQOL-BREF was selected because it is a generic measure of QOL and it was 
expected that the items on the IF-CPPQ would also assess similar domains of QOL. Scores on 
the WHOQOL-BREF were expected to show positive correlations with the IF-CPPQ.  
The Hospital Anxiety Depression Scale (HADS) (41)  
This is a validated 14-item questionnaire that assesses anxiety and depression (42). 
This questionnaire was included because it was designed for patients in non-psychiatric 
hospital clinics and research has shown anxiety and depression to mediate the impact of 
CPP (43). The HADS was predicted to have positive correlations with the IF-CPPQ.  
The Dyadic Sexual Communication Scale (DSC) (44)  
This 13-item questionnaire assesses perceptions of communication about sexual 
matters with relationship partners. Items are rated on a six-point scale from “Disagree 
strongly” to “Agree strongly”; the measure has good reliability and validity (44). The DSC 
was included because the IF-CPPQ contains items that assess sexual and relationship 
functioning. Because a higher score on the DSC indicates positive sexual communication, 
scores on the DSC were predicted to show negative correlations with the sexual and 
relationship functioning items on the IF-CPPQ.  
The Female Sexual Distress Scale-Revised (FSD-R) (45)  
This 13-item validated questionnaire assesses sex-related personal distress in 
women. Items are rated on a five-point scale from “Never” to “Always.” This questionnaire 
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shows good validity and reliability (45). The FSD-R was included because the IF-CPPQ 
contains sexual functioning items, which may relate to sexual distress. Scores on the FSD-R 
were expected to show positive correlations with the sexual functioning items on the IF-
CPPQ.  
The Social Desirability Response Set (SDRS)-5 (46)  
This five-item questionnaire was included to assess the degree to which IF-CPPQ 
responses were influenced by social desirability. The SDRS-5 has good reliability and validity 
(46).  
Procedure 
Questionnaires were administered via iSurvey, a University of Southampton online 
research survey tool. Women chose to take part by following the website link to the study. 
Participants were able to access the study link on National UK and international charities’ 
websites (including the Vulval Pain Society, the Pelvic Pain Support Network, and the 
Interstitial Cystitis Association), and on social media. After providing informed consent, 
participants completed the questionnaires. The study was approved by the institutional 
ethics committee. 
Data Analysis 
We used principal axis factor analysis (PAF) to assess the factor structure of the IF-
CPPQ and to test whether the scales were valid measures of hypothesised factors; published 
protocols/guides were followed (34, 35). PAF was used to examine the common variance 
and eliminate error variance within the factor structure of the IF-CPPQ. Oblimen rotation 
was employed as the rotation method to allow for correlations among the subscales (47). 
Factors were retained if they had an eigenvalue value greater than one (47) and were 
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excluded if: they had a loading of < 0.3 on factors; they had very low correlations with other 
items (r < .3); they correlated very highly with other items (r > 0.8); they had high loadings (> 
0.3) on multiple factors; they loaded on a factor but were markedly different to other items 
within the same factor e.g., a work-related item that loaded onto a sexual functioning 
factor. Although these criteria were used as guidelines, it was also important that the final 
solution made theoretical and clinical sense. To achieve this, several solutions were 
examined before deciding on the final model.  
Internal consistency testing was assessed using Cronbach’s alpha. Convergent 
validity was assessed using Pearson correlations between factor scores ofn the IF-CPPQ and 
scores on the other questionnaires (see Measures). The consistency and model fit of the 
resulting factor structure was assessed using confirmatory factor analysis (CFA), using 
maximum likelihood estimation. To determine how well the hypothesised factor model fit 
the data, three fit indices were used: the Chi-Square X2 test, the Comparative Fit Index (CFI), 
and the root mean square error of approximation (RMSEA). The X2 examines model fit by 
comparing the estimated correlation matrix under the model with the sample correlation 
matrix (48). Good model fit is indicated by a small nonsignificant X2 value, which reflects 
little discrepancy between the observed and hypothesised model (48). The CFI is an 
incremental fit index and compares the hypothesised model to a worst fitting or “null” 
model (48). A value greater or equal to 0.95 has been suggested to reflect acceptable fit 
(49). The RMSEA is considered to be a “badness-of-fit” index whereby a value of zero 
indicates the best fit (48). It reflects how closely the model fit approximates a reasonably 
fitted model, with good model fit having values <0.05 (50).  
The data were split in half and one half of the data was analysed using EFA to 
develop the hypothesised model or factor structure of the IF-CPPQ. The second half was 
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analysed using CFA to confirm the hypothesised model and assess its consistency. Pearson 
correlations between the IF-CPPQ and the validated questionnaires were obtained on the 
full data set. SPSS Statistics 24 was used to conduct the EFA and the add-on software, AMOS 
Graphics, was used to conduct the CFA. 
Results 
Participant characteristics  
Recruitment took place between June and August 2015. A total of 1,086 women 
started the study; after excluding those who did not complete all items on the IF-CPPQ, 969 
women were included in the analyses. Of these, 815 (84.12%) completed all items across all 
of the questionnaires.  
The mean age of the participants was 35.4 years (range = 18-78). The sample was 
predominantly White (93.1%), in full- or part-time employment (44.8% and 21.7%, 
respectively), well-educated (42.4% had a university degree) and in an exclusive/committed 
relationship (77.1%). Regarding country of residence, the majority (69.8%) were from 
Europe, followed by the U.S. (17.5%) and New Zealand (8.3%). Women reported a range of 
CPP-related conditions, the most common being endometriosis (68.4%), IBS (35.0%) and 
pelvic adhesions (23.8%). Table 1 presents sample demographic information and Table 2 
participants’ reported CPP severity.  
Factor analyses 
PAF was conducted on the 52 items with oblimen rotations. To ensure the results 
were reliable, data analysis was repeated and resulted in three different factor model 
solutions. Model 1 was achieved after 13, model 2 after 15, and model 3 after 11 iterations, 
respectively. The Kaiser-Meyer-Olkin (KMO) measure verified the sampling adequacy for the 
analyses: model 1, KMO = .89; model 2, KMO = .87; model 3, KMO = .89. Bartlett’s test of 
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sphericity was significant in all three models, p < .001, which indicates that the correlation 
matrix was significantly different from an identity matrix (i.e., that there were no 
relationships among the items). All three models contained five factors (or subscales), all 
with good internal consistency as measured by Cronbach’s alpha.  
Models 1 and 3 were very similar and consisted of almost identical factors: 
Psychological Impact, Sexual Impact, Relationship Impact, Occupational Impact, and 
Emotional Impact. They differed in their total number of items (model 1 had 25 items and 
model 3 had 27 items). There were also differences in the item factor loadings, particularly 
for the Psychological Impact, Relationship Impact, and the Emotional Impact factors. The 
first four factors in model 2 were the same as the other two models. The fifth factor in 
model 2 differed and included items reflecting impact on everyday functioning.  
Although all three models had good factor structures, model 3’s factor structure was 
more stable, demonstrated by the fact that models 1 and 3 comprised the same factors. The 
item loadings in model 3 also made better theoretical sense compared with model 1, even 
though the overall factors were the same. For example, item 43 (“I felt that I have not been 
“heard” or listened to by people close to me when I have talked about my pain”) loaded on 
the Relationship Impact factor in model 1, which seemed incongruent because the other 
items on this factor concerned issues relating specifically to one’s partner. In model 3, this 
item was replaced by item 33 (“I felt closer to my partner because of the pain”).  
 CFA was used to assess the fit of model 2 in comparison to model 3 to determine 
which of the two models was a better fit of the data. Because, as previously discussed, 
model 3 was superior to model 1, CFA was not conducted on model 1. Instead, a 1-factor 
model where all the items loaded onto one factor was also assessed to test the assumption 
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of unidimensionality. The results of the fit indices for all three models (i.e., Models 2 and 3 
and the unidimensional model), are summarised in Table 3.  
 The results in the top half of Table 3 are based on models 2 and 3, as indicated by 
the findings from the EFA. Both models resulted in a high Chi-square that was significant at 
p < .001, which is indicative of poor model fit. However, the Chi-square is known to be very 
sensitive to sample size and can be failed when conducted on large samples, even with very 
slight differences between the observed and predicted covariances (48, 51). This issue is 
overcome by the fit indices CFI and RMSEA, which indicated good model fit for both models 
2 and 3. The Chi-square, CFI, and RMSEA all showed an improvement of model fit when 
error covariances were estimated. Seven covariances between error variables were 
estimated in model 2 and 14 in model 3. Regression weights for models 2 and 3 were 
statistically significant at the p <0.001 level. Item 42 (“I felt anxious about experiencing pain 
during sexual activity in future relationships”) was the only item in both models with a p-
value equal to 0.001. Although this was statistically significant, this was the largest p-value 
compared with the rest of the items. When item 42 was removed, model fit was improved 
in both models, as indicated by a reduction in the Chi-square and RMSEA and increases in 
the CFI (see Table 3).  
The results of the Chi-square indicated that model 2 was a better fit of the data than 
model 3. However, the fit indices indicated both models had good fit. The CFI was only 
slightly higher for model 3, suggesting better model fit. Because the models mainly differed 
in their fifth factor (Psychological Impact in model 3 vs General Functioning in model 2), the 
characteristics of the distributions of the data for these factors were investigated. Both 
histograms showed negative skewness, which indicates a greater distribution of scores at 
the higher end of the scales. The General Functioning subscale was more negatively skewed, 
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with a skewness statistic of -1.14 (SE, 0.08) compared with -0.66 (SE, 0.08) for the 
Psychological Impact subscale. Kurtosis was 1.64 (SE, 0.16) for the General Functioning 
subscale and 0.00 (SE, 0.16) for the Psychological Impact subscale. Although it was expected 
that the data for these subscales would be negatively skewed, the results suggested that 
more women would score higher on the General Functioning subscale compared with the 
Psychological Impact subscale. Items from the Psychological Impact subscale reflect more 
severe psychological consequences of the pain. Thus, it was expected that women who are 
more severely affected by their pain would be more likely to endorse these items. In 
addition, there was more variability in scores for the Psychological Impact subscale 
compared with the General Functioning Subscale. This suggests that the Psychological 
Impact subscale would likely be better at discriminating between women that score high 
and those that score low on this subscale compared with the General Functioning subscales. 
Taken together, model 3 (with the removal of item 42) was chosen as the final solution for 
the IF-CPPQ.  
 Pearson correlations were computed between the IF-CPPQ subscales and the other 
validated questionnaires (see Table 4). All the correlations were significant at the p < .001 
level in the expected direction. With the exception of the Psychological Impact subscale, the 
correlations between social desirability scores (SDSR-5) and the IF-CPPQ subscale scores 
were not significant.  
Table 5 provides a summary of the results for model 3, which contained 27 items 
that in combination explained 62.75% of the variance. Table 6 presents the correlations 
between the five factors in model 3. All the subscales had good reliabilities (r’s between .72-
.91). and the Cronbach’s alpha of the IF-CPPQ overall was 0.64. The final version of the IF-
CPPQ is shown in Appendix A. 
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Discussion 
Main findings 
This study presents the development and validation of a new questionnaire 
assessing the impact of CPP on women, the IF-CPPQ. The results show the questionnaire is a 
reliable and valid measure of the impact of CPP. Based on both EFA and CFA, the IF-CPPQ 
has five subscales: Emotional Impact, Sexual Impact, Relationship Impact, Occupational 
Impact, and Psychological Impact. Women with a number of different diagnoses associated 
with CPP were recruited, which is reflective of this population.  (52) 
Several of the quality measurement properties recommended by Terwee et al. (32) 
were assessed and achieved in the current study. Content validity was achieved through 
previous qualitative work to ensure the items of the IF-CPPQ were representative of the 
different factors related to the impact of CPP (29, 30).  Internal consistency was assessed 
and achieved using Cronbach’s alpha in the current study. Concurrent and construct 
(convergent and discriminant) validity were assessed and achieved by correlating the IF-
CPPQ total and subscale scores with other validated measures that assess related 
constructs. Although most of the quality criteria have been assessed and achieved, two 
important measurement properties outlined by Terwee and colleagues (32) – 
responsiveness and interpretability – were not evaluated. Future studies should assess the 
responsiveness and interpretability of the IF-CPPQ to determine whether the questionnaire 
is able to detect clinically meaningful changes in the impact of CPP over time, such as the 
minimal clinically important difference (MCID) (53). The MCID can be defined as the 
minimum change in scores in the domain of interest that patients perceive to be beneficial 
and that lead to a change in the patient’s management (53). Translating the changes in 
measurement scores so that they are clinically meaningful is necessary for interpreting 
 16 
research results (53). In the context of CPP, confirming the MCID is important to determine 
how women with CPP evaluate the treatments they receive. 
The remaining measurement properties that were not assessed included predictive 
validity, test-retest reliability, and floor and ceiling effects. However, these properties are of 
uncertain relevance in relation to the IF-CPPQ. This is because CPP is a long-term condition 
and usually very unpredictable. Therefore, scores on the IF-CPPQ will likely vary over 
different time points. Finally, due to the debilitating nature of CPP, many participants will 
likely score relatively high on the IF-CPPQ, indicating ceiling effects. Consequently, a normal 
distribution is not expected and would be difficult to achieve with this particular sample. 
There are several advantages of the IF-CPPQ over previously published 
questionnaires. First, the items were generated based on qualitative interviews and were 
piloted in “think-aloud” interviews, in both instances with women experiencing CPP (29, 30). 
The think-aloud method involves asking participants to say out loud their thought processes 
during a task (54). This method allowed the researchers to determine the acceptability and 
suitability of the questions for women with CPP.  Second, the IF-CPPQ assesses the impact of 
CPP on several facets of women’s lives. Though consideration of the emotional and 
psychological impact of CPP has historically been somewhat neglected in CPP research (55-
57), there is now a growing recognition of the importance of various dimensions of QoL in 
relation to CPP (15, 20).  The IF-CPPQ validates and recognises the multidimensional impact 
of CPP. Other areas that are often not covered by existing questionnaires include 
relationship and sexual functioning (15-17, 19). The IF-CPPQ includes two subscales that 
assess the impact of CPP on relationships and on sexual functioning; items on these 
subscales were derived from themes identified in a qualitative study that explored the 
impact of CPP (29). Regarding sexual functioning, women with CPP report significantly 
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decreased sexual function in comparison to pain-free women, as well as higher levels of 
pain with intercourse, sexual avoidance, and sexual dissatisfaction (22, 43). Many women 
report that their CPP has had a negative impact on their relationships beyond sexual 
functioning (29), but the impact of CPP on women’s relationships with partners has been 
given even less attention compared with sexual functioning (43, 58, 59). It is important to 
assess the impact of CPP on personal relationships separately from sexual functioning.  
Third, because the items on the IF-CPPQ are not tied to specific CPP conditions, it can 
be completed by women who have no formal diagnosis and by women with multiple CPP-
related conditions. Although some women receive a formal diagnosis for their pain, such as 
endometriosis, it is not uncommon for women with CPP to have received no diagnosis (60, 
61). The IF-CPPQ response options also allow women to indicate how much they are 
affected by their pain by specifying how much they agree or disagree with the items. In 
contrast, other questionnaires such as the EHP-30 use response categories that indicate 
how often particular events have occurred (e.g., “Never,” “Sometimes,” and “Always”). 
While there is some overlap between the VPAQ and the IF-CPPQ, the former questionnaire 
aims to assist in the screening and diagnosis of vulvar pain, while the IF-CPPQ aims to assess 
the impact of CPP on a number of QoL variables. A number of questions on the VPAQ relate 
specifically to women with vulvar pain (e.g., pain with using tampons), whereas all questions 
on the IF-CPPQ are potentially relevant to women with all types of CPP.    
The final IF-CPPQ comprises 26 items. Although the length is comparable to other 
questionnaires that are considered acceptable for this clinical population (15, 20), there is 
still the potential for participants to experience burden when completing questionnaires. 
This is especially relevant for clinical research studies where participants are asked to 
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complete multiple measures at a given time. Future research can focus on developing a 
short version of the IF-CPPQ so that it is accessible to various research and clinical contexts.     
Previous studies have used generic measures to assess improvements in CPP across a 
range of outcomes, including pain, quality of life, and sexual functioning. Examples of 
measures used include the Short Form-12 (62), the Female Sexual Function Index (63), and 
the Brief Pain Inventory (64). The IF-CPPQ can be used pre- and post- treatment to assess 
improvement alongside additional generic measures. Moreover, the IF-CPPQ can be used as 
an addition and not necessarily as a replacement for disease- specific tools such as the EHP-
30 for endometriosis (15), in conditions where women have received a diagnosis.  
Strengths and Limitations 
The current study had some notable strengths. As discussed above, a patient-led 
approach was used in developing the IF-CPPQ and the items concern how CPP has impacted 
women’s lives from their perspective (29). The previous qualitative data obtained provided 
good insight into the different ways women with CPP can be affected by their pain. 
Feedback on the initial items was also gained from women with CPP in a think-aloud study, 
which ensured the items were comprehensible and provided an opportunity to remove or 
reword ambiguous items (30, 31). Both of these earlier studies were important in ensuring 
the IF-CPPQ had good content and face validity. Finally, another strength was the large 
sample size that allowed for both EFA and CFA to be conducted, which provided better 
support for the overall factor structure of the IF-CPPQ.  
Study limitations also need to be acknowledged. Although criteria were used to help 
determine an acceptable factor solution, some of the decision making process in EFA can be 
viewed as subjective or arbitrary e.g., the eigenvalue-greater-than-one rule and scree test 
(65). There are also limitations with the use of fit indices in CFA. Values of fit statistics only 
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indicate the average or overall fit of a model (48). Therefore, even if some aspects of the 
model poorly fit the data, the value of fit statistics can still be favourable. In addition, there 
is little relation between values of fit indices and the degree or type of misspecification i.e., 
they do not indicate how much the model departs from the data (48). Finally, fit statistics do 
not indicate whether the results are theoretically meaningful (48).  
Thresholds for fit indices that are widely used (49) were intended to be used as 
“rules of thumb” only. However, there is the issue of “fit statistic tunnel vision” whereby 
researchers become so preoccupied with fit statistics that other information e.g., whether 
the parameter estimates actually make sense, is overlooked (48). Therefore, as with EFA, it 
is important for researchers to use interpretation guided by theoretical understanding of 
their data (65). Furthermore, while the internal consistency of the individual scales showed 
excellent reliability, Cronbach’s alpha for the overall scale score was 0.64. Though this score 
still indicates good reliability, it is somewhat low compared to the individual scale scores.    
Another study limitation concerns the method of recruitment. Because the study 
was administered online it may have been open to potential selection bias. This is because 
women with more complaints or more severe CPP are more likely to seek out help. 
Therefore, women with more severe CPP may be over-represented in the current sample 
compared with the population of women with CPP more generally. Moreover, because this 
study was online, recruitment relied upon a self-selected sample from the general 
population. This meant that clinical confirmation of reported diagnoses was missing.  The 
self-reported nature of the sample also meant there was limited control on recruiting more 
balanced proportions of women with certain CPP diagnoses. Future research should validate 
the IF-CPPQ in well-phenotyped CPP sub-populations (e.g., endometriosis, IBS, BPS). This 
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would demonstrate that the IF-CPPQ can be validly applied to the various CPP sub-
populations.   
The development of the questionnaire did not involve any input from health 
professionals. Although the focus is on the impact of CPP from the women’s perspective, 
health practitioners involved in the management and treatment of CPP may have 
knowledge of additional areas of life that are impacted by the pain and which may have 
been missed.  
A final limitation concerns the sociodemographic characteristics of the sample; most 
participants were White and were well-educated. It is important for future studies to recruit 
participants with more diverse backgrounds and to assess whether the measure is suitable 
for women with different cultural backgrounds. 
Conclusions  
The IF-CPPQ questionnaire has the potential to be used in several ways. First, the 
measure can be used to select women who have been severely impacted by their CPP into 
trials of interventions/treatments. Because the IF-CPPQ is not disease-specific, it can assess 
the impact of CPP in women without any formal diagnoses. (66, 67) The IF-CPPQ could also 
potentially aid communication between women with CPP and their health care 
professionals so that women can communicate exactly how their pain is impacting their 
lives rather than just their pain levels. While the IF-CPPQ has the potential for multiple uses 
within research and clinical practice, further research is needed to determine its ability to 
detect clinically meaningful changes.   
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Appendix A: Final 26 item IF-CPPQ  
This questionnaire is intended to be used by adult women who experience chronic pelvic 
pain. The questionnaire aims to assess the impact of chronic pelvic pain on women’s lives in 
terms of everyday activities (e.g. being able to sit, household tasks, and hobbies), being able 
to work, socialising, relationships, and sexual relationships. Thinking about the past month 
only, please indicate how much you agree or disagree with the following statements. The 
questions concern your chronic pelvic pain. Please answer each question with respect to 
your chronic pelvic pain. 
 
Answer format: 
Response categories:         Scoring:    
Strongly disagree     0 
Disagree     1 
Neither agree nor disagree   2 
Agree      3 
Strongly agree     4 
 
1) I felt embarrassed about my pain 
2)  I have had difficulties communicating with my partner about my pain* 
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3) I felt controlled by my pain 
4) I have felt socially isolated because of the pain 
5) I felt unable to cope with my pain 
6) I felt less connected to my partner because of the pain* 
7) I felt despair about my pain 
8) I have avoided sexual activity because of the pain* 
9) I have gotten upset easily because of the pain 
10) I felt that my pain has taken away my life 
11) Sexual activity has been very painful (either during or after sexual activity)* 
12)  The pain has made me feel less confident 
13) I took time off work (including any voluntary work or education) because of the 
pain* 
14) The pain has reduced my ability to feel sexually aroused (either during partnered 
sexual activity or during masturbation)* 
15) I experienced low mood because of the pain 
16) I have felt negatively judged at work because of my pain* 
17) I have had thoughts about ending my life because of the pain 
18) The pain has reduced my desire to engage in sexual activity*  
19) I felt closer to my partner because of my pain* 
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20) I felt irritable or snappy because of the pain 
21) I have been unable to enjoy sexual activity because of the pain* 
22) I felt angry because of the pain 
23) My pain has not been taken seriously by my partner* 
24) The pain has negatively affected my performance at work (including any voluntary 
work or education)* 
25) I felt guilty for not being able to engage in sexual activity because of the pain* 
26) I felt frustrated at not being able to engage in sexual activity* 
 
*indicates that these questions will have an additional response option – “Not applicable”  
 
Tables 
Table 1 
EFA participants (N = 483), CFA participants (N = 484), and overall dataset (N = 969) 
Age:  
EFA  CFA  Total Sample 
Mean, (SD)     35.1 (11.92)  35.7 (12.0) 35.4 (11.96) 
Range      18-76  18-78  18-78 
Experience of pain (years):  
EFA  CFA  Total Sample 
Mean, (SD)    10.80 (8.67) 11.25 (9.28) 10.99 (8.98) 
Range     0-56  0-50  0-56    
Years since diagnosis: 
EFA  CFA  Total Sample 
Mean, (SD)    5.17 (6.0) 5.53 (6.67) 5.32 (6.31)  
Range     0-45.08 0-40.00 0-45.08 
 
Diagnoses (%): 
     EFA  CFA  Total Sample 
Endometriosis    67.5  69.3  68.4 
Vulvodynia    12.4  9.3  10.8 
Polycystic ovary syndrome  13.9  12.1  13.0 
Pelvic organ prolapse   3.3  3.5  3.4 
Pelvic adhesions   26.1  21.6  23.8 
Interstitial Cystitis   19.3  20.2  19.7 
Irritable bowel syndrome  36.6  33.3  35.0 
Pudendal neuralgia   2.3  2.1  2.2 
Pelvic inflammatory disease  8.1  7.8  7.9 
No diagnosis/unknown  11.2  9.3  10.2 
Tables
 Ethnic background (%):  
     EFA  CFA  Total Sample   
White     93.6  92.6  93.1 
Mixed / multiple ethnic groups  2.7  2.5  2.6 
Asian      1.2  1.6  1.4 
Black/African/Caribbean   1.0  1.6  1.3 
Other ethnic group    0.8  1.0  0.9 
Country resident in (%): 
     EFA  CFA  Total Sample  
Europe     71.8  68  69.8 
South America   0.4  0.4  0.3 
Australia    1.2  1.9  1.5 
Canada    1.0  1.9  1.4 
East Asia    0.0  0.6  0.3 
New Zealand    8.7  7.8  8.3 
United States    16.6  18.5  17.5 
 
Employment status (%):          
     EFA  CFA  Total Sample  
Homemaker     11.2  10.5  10.8 
Paid full-time employment  40.6  49.0  44.8 
Paid part-time employment   21.9  21.4  21.7 
Retired     6.0  6.2  6.1 
Unemployed     19  10.9  15.0 
Student (%):    
     EFA  CFA  Total Sample 
Non-student    80.3  82.7  81.2 
Full-time student    10.8  9.1  9.9 
Part-time student    7.2  7.6  7.4 
Highest education level (%): 
     EFA  CFA  Total Sample 
College or Equivalent    30.2  26.5  28.4 
No qualifications    1.2  0.6  0.9 
Other vocational/ 
work-related qualifications   4.3  4.9  4.6 
Prefer not to say    0.8  0.8  0.8 
Professional qualification   8.9  8.8  8.9 
Secondary School/ High School  13.7  12.8  13.2 
University Bachelor’s degree  
or equivalent     25.3  27.0  26.1 
University Postgraduate degree  
or equivalent     14.9  17.7  16.3 
 
Relationship status (%): 
     EFA  CFA  Total Sample 
Casual relationship    1.9  1.6  1.8 
Exclusive/committed relationship  76.8  77.4  77.1 
Single      18.8  19.3  19.1 
Marital status (%): 
     EFA  CFA  Total Sample 
Divorced/separated    8.9  6.8  7.8 
Civil partnership    3.9  3.9  3.9 
Married     38.5  46.9  42.7 
Single     46.2  40.3  43.2 
Widowed     0.8  1.0  0.9 
Note: “EFA” – Exploratory factor analysis; “CFA” – Confirmatory factor analysis
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Table 2 
 Pain questions  
Question      x̅ (SD) 
N= 969 
How would you rate your  
current pain level?     5.33 (2.43) 
How would you rate your pain at its  
worst over the past month?    8.07 (1.82) 
How would you rate your pain at its  
best over the past month?    3.29 (2.51) 
N=275 
If the past month was not a typical  
one, how would you rate your  
average experience of pain  
over a typical month?     6.50 (2.15) 
Note: Scores on these questions ranged from “0 – No Pain” to “10 – Worst imaginable pain”. 
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Table 3 
 Goodness of fit indices for Models 2, 3, and the unidimensional model (N=462) 
    𝜒2 (df)   RMSEA CFI 
Unidimensional  3558.78 (324)** 0.15  0.51 
Model 2   513.41 (258)** 0.05  0.95 
Model 3   588.78 (300)** 0.05  0.96 
Removal of item 42:  𝜒2 (df)   RMSEA CFI 
Model 2   437.51 (235)** 0.04  0.96 
Model 3   502.20 (274)** 0.04  0.97 
Note: “**” - Significant at p < .001; Good fit is indicated by CFI ≥ .95 and RMSEA ≤ .05 
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Table 4 
Pearson correlations between the IF-CPPQ subscales and total score with validated measures  
Factor  Questionnaire  Expected correlation  r Value r2 
direction  
Emotional  HADS-A  Positive    0.49**  0.24 
Impact  HADS-D  Positive    0.44**  0.19 
  WHO_PSYCH Negative   -0.46** 0.21 
SDRS-5                  Positive                          0.048          0.002 
Sexual  DSC   Negative   -0.18** 0.03 
Impact  FSDS-R  Positive   0.6**  0.36 
SDRS-5                      Positive                            0.049         0.002 
Relationship DSC   Negative    -0.4**  0.16 
Impact  FSDR-R  Positive   0.39**  0.15 
  WHO_SOCIAL Negative   -0.45** 0.20 
SDRS-5                       Positive                           0.035          0.001 
Occupational PDI   Positive   0.47**  0.22 
Impact  WHO_PHYS  Negative   -0.5**  0.25 
SDRS-5                       Positive                           0.072          0.005 
Psychological HADS-A  Positive   0.5**  0.25 
Impact  HADS-D  Positive    0.59**  0.35 
  WHO_PSYCH Negative   -0.6**  0.36 
SDRS-5                       Positive                           0.123**       0.015 
IF-CPP Tot WHO-1  Negative   -0.37** 0.14 
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  WHO-2  Negative   -0.38** 0.14 
  PDI   Positive   0.44**  0.19 
SDRS-5                       Positive                          0.075          0.006 
Note: “HADS-A” - The Hospital Anxiety and Depression Scale – Anxiety scale; “HADS-D” - The Hospital Anxiety 
and Depression Scale – Depression scale; “DSC” - The Dyadic Sexual Communications Scale; “FSDS-R” - The 
Female Sexual Distress Scale – Revised; “PDI” - The Pain Disability Index; “WHO_PHYS” – The WHO quality of 
life-Bref physical health subscale; “WHO_PSYCH” - The WHO quality of life-Bref psychological health subscale; 
“WHO_SOCIAL” - The WHO quality of life-Bref social health subscale; “WHO-1” - The WHO quality of life-Bref 
overall quality of life; “WHO-2” - The WHO quality of life-Bref overall health; “SDRS-5” – The Social 
Desirability Response Set-5; “**” – p < 0.001. 
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Table 5 
Summary of PAF rotated factor loadings for Model 3 (Superior model) / 27 items 
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 
Psychological Impact:  
 (6) I felt embarrassed about my pain       .55 
(9) I felt controlled by my pain       .54 
(11) I have felt socially isolated because of the pain    .67 
(13) I felt unable to cope with my pain      .74 
(15) I felt despair about my pain       .57 
(20) I felt that my pain has taken over my life     .46 
(22) The pain has made me feel less confident with myself   .50 
(31) I have had thoughts about ending my life because of the pain   .42  
Sexual Impact: 
                 (Continued on next page) 
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Table 5 continued 
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 
(16) I avoided sexual activity because of the pain      .62 
(21) Sexual activity has been very painful  
(either during or after sexual activity)         .70 
(24) The pain has reduced my ability to feel sexually aroused  
(either during partnered sexual activity or during masturbation)      .69 
(32) The pain has reduced my desire to engage in sexual activity     .79 
(36) I have been unable to enjoy sexual activity because of the pain    .89 
(42) I felt anxious about experiencing pain during sexual activity in   
future relationships          .63 
(46) I felt guilty for not being able to engage in sexual activity because of the pain  .78 
(50) I felt frustrated at not being able to engage in sexual activity     .82  
Relationship Impact 
                 (Continued on next page) 
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Table 5 continued 
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 
 (8) I have had difficulties communicating with my partner about my pain     .60 
(14) I felt less connected to my partner because of the pain       .52 
(39) My pain has not been taken seriously by my partner        .66 
(33) I felt closer to my partner because of my pain        .63 
Occupational Impact 
(23) I took time off work (including any voluntary work or education)        .75 
because of the pain 
(28) I have felt negatively judged at work because of my pain         .52 
(44) The pain has negatively affected my performance at work  
(including any voluntary work or education)            .77  
Emotional Impact 
(Continued on next page) 
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Table 5 continued 
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 
 (18) I have gotten upset easily because of my pain             .58 
(26) I experienced low mood because of the pain             .42 
(35) I have felt irritable or snappy because of the pain            .77 
(38) I felt angry because of the pain               .60  
Eigenvalue          9.09  3.39  1.84  1.49  1.14 
%Variance explained         33.66  12.56  6.82  5.51  4.21 
Cronbach’s α:          .84  .91  .72  .76  .75 
Note. Numbers in parentheses “()” indicate the item number in the original questionnaire 
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Table 6 
Correlations between factors in Model 3 
  1 2 3 4 5 
Emotion - 
Sexual  .330 - 
Relationship .357 .671 - 
Occupation .466 .157 .105 - 
Psych  873 .398 .369 .52 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
